Wave Life Sciences Ltd., an RNA medicines company, has announced its first clinical trial application for WVE-006, a revolutionary RNA editing therapeutic candidate aimed at treating alpha-1 antitrypsin deficiency (AATD). AATD is a genetic disorder causing lung and...
Six cohorts, totaling 50 late-stage cancer patients, received STP707 four times monthly by intravenous infusion at escalating dosages. All cohorts demonstrated a strong safety profile with no dose-limiting toxicity noted for any dosing cohort and the treated patients...
